Nov 28, 2023 / 03:00PM GMT
Allison Marie Bratzel - Piper Sandler & Co., Research Division - VP and Senior Research Analyst
Let's go ahead and get started. So thanks, everyone, for joining us. My name is Ally Bratzel, one of the senior biotech analysts here at Piper Sandler, and it's my pleasure to introduce this morning Ionis. So joining us today, we have Brett Monia, CEO. So thanks for joining.
Just to go over the format, this is meant to be informal. If anyone in the audience has a question, feel free, just raise your hand, speak up, and we will get your question asked.
Questions and Answers:
Allison Marie Bratzel - Piper Sandler & Co., Research Division - VP and Senior Research AnalystBut I will go ahead and get us started off. I have a couple of pages worth of questions here. So maybe, Brett, just kind of an intro question. I think we all know Ionis has a long history as a leading antisense and ASO company. So just to kick us off, go over the evolution of your key late-stage programs, eplontersen, donidalorsen and olezarsen, how that fits in the Ionis
Trustpilot
